Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIMO-CABG II pexelizumab in patients undergoing CABG with cardiopulmonary bypass
2004-000140-25Phase 3Completed
- Sponsor
- Procter & Gamble
- Start
- Feb 2005
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Systemic Inflammatory Response Syndrome (SIRS) and myocardial infarction (MI) comparing Pexelizumab with Placebo (2 arms). Started Feb 2005; status: completed.
02
Drugs
pexelizumab
03
Conditions
Systemic Inflammatory Response Syndrome (SIRS)myocardial infarction (MI)
Beyond the preview
Go deeper on 2004-000140-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000140-25.